Jubilant HollisterStier Signs Manufacturing Agreement with Eli Lilly for COVID-19 Therapeutic Bamlanivimab

Ad - Bora Pharmaceuticals

Jubilant Life Sciences Ltd, an integrated global Pharmaceuticals and Life Sciences Company, recently announced that its wholly-owned subsidiary, Jubilant Pharma Limited, through one of its subsidiaries, Jubilant HollisterStier LLC , has signed new contract with Eli Lilly for contract manufacturing of a treatment for COVID-19. The drug will be manufactured at the Spokane, Washington, USA facility of the Company.

Commenting on the occasion, Mr. Pramod Yadav, CEO, Jubilant Pharma Limited, said: “We are delighted to partner with our customers and contribute towards the fight against COVID-19 pandemic. Our CMO business, an established player in the North American market, has strong capabilities in the manufacturing of sterile injectables (both liquid and lyophilisation) and we are committed to continue exceeding expectations of our customers in this business. One of our subsidiaries, Jubilant HollisterStier LLC, has signed a contract with Eli Lilly and Company (Lilly), for contract manufacturing of Bamlanivimab, a drug that has been granted Emergency Use Authorization by the FDA for emergency use as a treatment of COVID 19. Jubilant HollisterStier is part of Lilly’s network of external manufacturing organizations that is producing the drug. The drug will be manufactured by Jubilant HollisterStier at the company’s Spokane, Washington, USA facility.

Advertisement